Skip to content

Psychedelic-assisted therapy: all studies

Page 254 of 294: studies 2,531 to 2,540 of 2,936, newest first. Back to the psychedelic-assisted therapy overview

Research

Cyberdelics in context: On the prospects and challenges of mind-manifesting technologies.

Frontiers in Psychology 2022 Ido Hartogsohn 19 citations

The concept of cyberdelics emerged in the 1980s and 1990s as an umbrella term denoting the nexus connecting cybernetic (digital) technologies and psychedelic (mind manifesting) drugs. Cyberdelic technologies, in particular the then newly emerging field of virtual reality, were touted by psychedelic cultural icons including Timothy Leary and Terence McKenna as auguring a new era of digital...

DOI: 10.3389/fpsyg.2022.1073235 (opens in new tab) Full text (opens in new tab) Consumerism Cyberdelics Imaginaries Neurofeedback +8

Psychedelic Science of Spirituality and Religion: An Attachment-Informed Agenda Proposal

December 25, 2021 Aaron D. Cherniak, Joel Gruneau Brulin, Mario Mikulincer et al. 4 citations preprint

In this paper, we set an agenda for a psychedelic science of spirituality and religion, based on a synthesis of attachment theory with the Relaxed Beliefs Under pSychedelics (REBUS) model. Attachment theory proposes that people develop internal working models (IWMs) of interactions with others from their relational experiences with caregivers. Such IWMs then function as high-level priors...

DOI: 10.31234/osf.io/x58m9 (opens in new tab) Full text (opens in new tab) Spirituality Attachment theory Psychological intervention Psychotherapist +4

Ketamine infusion therapy in treatment-resistant depression

Psychiatriki December 20, 2021 Τheodosios Ε Christodoulakis 1 citation

Τhe Food and Drug Administration (FDA) approval of the use of S-ketamine in the form of nasal spray for the treatment of treatment-resistant depression, launched a new category of therapeutic agents in psychiatry. A well-known class of substances, psychedelics, are introduced with a 30-year delay in the treatment of mental disorders. Intravenous ketamine infusion has been studied in the...

The gluco-regulatory effects of 3,4- Methylenedioxymethamphetamine (MDMA): A controlled n-of-2 self-experimentation

Zenodo (CERN European Organization for Nuclear Research) December 18, 2021 Harriet A. Carroll preprint

Background: Psychedelic drugs are increasingly being researched for their therapeutic properties in terms of treatment resistant mental illnesses. However, little is known about how they impact metabolism, which has implications for those with metabolic diseases such as diabetes. Hypohydration has been argued by some to cause glucose dysregulation, particularly due to elevations in arginine...

DOI: 10.5281/zenodo.5791165 (opens in new tab) MDMA Pharmacology Self-administration

Towards the Use of Whole Natural Products in Psychedelic Research and Therapy: Synergy, Multi-Target Profiles, and Beyond

Frontiers in Natural Product Chemistry December 6, 2021 5 citations

Interest in psychoactive ethnobotanicals such as ayahuasca or Psilocybe mushrooms for clinical uses has increased over the last two decades. While clinical and experimental approaches have focused on using isolated compounds of interest (such as psilocybin), an emerging trend in drug discovery involves a more comprehensive approach. The polypharmacology paradigm, as it has been named, suggests...

DOI: 10.2174/9781681089379121080005 (opens in new tab) Natural archaeology Psychotherapist

Psychedelic psychodrama: Raising and expanding consciousness in Jane Arden’s The Other Side of the Underneath (1973)

History of the Human Sciences December 1, 2021 Sophia Satchell-Baeza

Jane Arden’s debut feature film The Other Side of the Underneath (1973) is an adaptation of the radical feminist play A New Communion for Freaks, Prophets and Witches (1971). In both the play and the later film, the all-female cast re-enact personal and archetypal situations using autobiographical material, which was collectively gathered from group therapy sessions led by the director....

Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs.

International Journal of Drug Policy December 1, 2021 David B. Yaden, Andrea P Berghella, Paul S. Regier et al.

Several pilot studies have provided evidence supporting the potential of classic psychedelics like psilocybin in the treatment of substance use disorders (SUDs). If larger trials confirm efficacy, classic psychedelic-assisted psychotherapy may eventually be integrated into existing addiction treatments such as cognitive behavioral therapy, contingency management, and medication-assisted...

P.0729 Highlights of psychedelic history and current research on psilocybin application for treatment of depression – a comprehensive literature review

European Neuropsychopharmacology December 1, 2021 S. Penedos, C. Ramos, M. Miguel et al. 1 citation

Introduction: Psychedelics have seen various labels: mystical sacrament aids, potential interrogation tools for the Cold War, agents for social change in the Hippie counter movement, a panacea for various mental disorders, and a tool to “hack” of the psyche. This has led to their reputation as both societal threat and a psychopharmacological breakthrough. After the loss of data on over 1000...

Anxiety-related Symptoms following the Sporadic Use of Ecstasy – A Case Study

Journal of Psychoactive Drugs November 25, 2021 Tomislav Majić, Lasse Brandt, Christiane Montag 3 citations

3,4-methylenedioxymethamphetamine (MDMA/"ecstasy") is widespread in the electronic club scene, but MDMA has also been suggested for the treatment of anxiety spectrum disorders like posttraumatic stress disorder (PTSD) and social anxiety in autistic adults. Here, we report a case of a high functioning 24-old student with a sporadic recreational use of ecstasy, and a history of a single episode...

An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant Depression.

Frontiers in Psychiatry November 24, 2021 Sherry-Anne Muscat, Glenn Hartelius, Courtenay Richards Crouch et al. 47 citations

Research over the last two decades has established ketamine as a safe, effective, fast-acting, and sustained antidepressant that significantly reduces adverse symptoms associated with depression, even in patients who are treatment resistant. Much of this research has evolved within the framework of several independent branches of scientific inquiry: in addition to the study of ketamine is a...

DOI: 10.3389/fpsyt.2021.710338 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Therapeutic outcomes Ketamine therapy ketamine Psychotherapy supportive treatments +2